Drug repurposing strategy II: from approved drugs to agri-fungicide leads

J Antibiot (Tokyo). 2023 Mar;76(3):131-182. doi: 10.1038/s41429-023-00594-2. Epub 2023 Jan 27.

Abstract

Epidemic diseases of crops caused by fungi deeply affected the course of human history and processed a major restriction on social and economic development. However, with the enormous misuse of existing antimicrobial drugs, an increasing number of fungi have developed serious resistance to them, making the diseases caused by pathogenic fungi even more challenging to control. Drug repurposing is an attractive alternative, it requires less time and investment in the drug development process than traditional R&D strategies. In this work, we screened 600 existing commercially available drugs, some of which had previously unknown activity against pathogenic fungi. From the primary screen at a fixed concentration of 100 μg/mL, 120, 162, 167, 85, 102, and 82 drugs were found to be effective against Rhizoctonia solani, Sclerotinia sclerotiorum, Botrytis cinerea, Phytophthora capsici, Fusarium graminearum and Fusarium oxysporum, respectively. They were divided into nine groups lead compounds, including quinoline alkaloids, benzimidazoles/carbamate esters, azoles, isothiazoles, pyrimidines, pyridines, piperidines/piperazines, ionic liquids and miscellaneous group, and simple structure-activity relationship analysis was carried out. Comparison with fungicides to identify the most promising drugs or lead structures for the development of new antifungal agents in agriculture.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Infective Agents* / pharmacology
  • Antifungal Agents / pharmacology
  • Drug Repositioning
  • Fungicides, Industrial* / chemistry
  • Fusarium*
  • Humans
  • Structure-Activity Relationship

Substances

  • Fungicides, Industrial
  • Antifungal Agents
  • Anti-Infective Agents